Allogene Therapeutics Stock News

After William Blair and Canaccord Genuity gave Allogene Therapeutics (NASDAQ: ALLO) a Buy rating last month, the company received another

SunTrust Banks assumed coverage on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research report released on Monday, BenzingaRatingsTable reports. The firm issued a buy rating and a $29.00 price

Atara Biotherapeutics recently updated that its lead program, tab-cel, remains on track despite the COVID-19 pandemic. Tab-cel is the most advanced allogeneic T

Monday's top analyst upgrades and downgrades included Alibaba, Apple, American Express, Brinker, Caterpillar, Chipotle Mexican Grill, Dell, Halliburton, Palo Alto Networks, Starbucks, Texas Instrument

Allogene Therapeutics (NASDAQ:ALLO) initiated with Buy rating and $29 (28% upside) price target at SunTrust.Allscripts Healthcare Solutions (NASDAQ:MDRX) initiated with Market Perform rating and $8 (1

Goldman Sachs Group Inc. grew its holdings in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 66.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Comm

Allena Pharmaceuticals (NASDAQ:ALNA) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of the

Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.

Franklin Resources Inc. trimmed its position in Allogene Therapeutics Inc (NASDAQ:ALLO) by 22.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 610,697 shares of

Will the new coronavirus cause a recession in US in the next 6 months? On February 27th, we put the probability at 75% and we predicted that the market will decline by at least 20% in (Recession is Im

Zacks Investment Research upgraded shares of Allogene Therapeutics (NASDAQ:ALLO) from a hold rating to a buy rating in a research report report published on Thursday morning, Zacks.com reports. They c

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

Victory Capital Management Inc. boosted its position in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 41.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 12,364 shares of the

Allogene Therapeutics (NASDAQ:ALLO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According to

SOUTH SAN FRANCISCO, Calif., April 01, 2020 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T.